- Home
- IBAC vs MDWD Comparison
IBAC vs MDWD Comparison
Compare IBAC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBAC
- MDWD
- Stock Information
- Founded
- IBAC 2020
- MDWD 2000
- Country
- IBAC United States
- MDWD Israel
- Employees
- IBAC N/A
- MDWD N/A
- Industry
- IBAC
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- IBAC
- MDWD Health Care
- Exchange
- IBAC Nasdaq
- MDWD Nasdaq
- Market Cap
- IBAC 159.4M
- MDWD 184.8M
- IPO Year
- IBAC 2024
- MDWD 2014
- Fundamental
- Price
- IBAC $10.18
- MDWD $18.68
- Analyst Decision
- IBAC
- MDWD Strong Buy
- Analyst Count
- IBAC 0
- MDWD 1
- Target Price
- IBAC N/A
- MDWD $25.00
- AVG Volume (30 Days)
- IBAC 91.1K
- MDWD 64.8K
- Earning Date
- IBAC 01-01-0001
- MDWD 11-26-2024
- Dividend Yield
- IBAC N/A
- MDWD N/A
- EPS Growth
- IBAC N/A
- MDWD N/A
- EPS
- IBAC 0.19
- MDWD N/A
- Revenue
- IBAC N/A
- MDWD $19,720,000.00
- Revenue This Year
- IBAC N/A
- MDWD $10.37
- Revenue Next Year
- IBAC N/A
- MDWD $26.36
- P/E Ratio
- IBAC $52.42
- MDWD N/A
- Revenue Growth
- IBAC N/A
- MDWD N/A
- 52 Week Low
- IBAC $9.93
- MDWD $11.04
- 52 Week High
- IBAC $10.26
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- IBAC N/A
- MDWD 55.45
- Support Level
- IBAC N/A
- MDWD $17.47
- Resistance Level
- IBAC N/A
- MDWD $18.54
- Average True Range (ATR)
- IBAC 0.00
- MDWD 0.97
- MACD
- IBAC 0.00
- MDWD 0.07
- Stochastic Oscillator
- IBAC 0.00
- MDWD 71.05
About IBAC IB Acquisition Corp. Common Stock
IB Acquisition Corp is a blank check company.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.